First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)
June 15, 2023 11:31 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
May 15, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
May 11, 2023 07:00 ET
|
First Wave BioPharma, Inc.
Top line data read-out on track for July 2023 BOCA RATON, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a...
First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference
May 02, 2023 07:30 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
April 25, 2023 07:00 ET
|
First Wave BioPharma, Inc.
Three U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in July 2023 BOCA RATON, Fla., April 25, 2023 (GLOBE...
First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference
February 21, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
February 13, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
January 25, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency
January 13, 2023 16:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...